Open access
Open access
Powered by Google Translator Translator

Global & Public Health (all articles)

[Preprint] More data showing longer dosing interval increases immune response after Pfizer-BioNTech’s COVID-19 vaccine.

26 Sep, 2021 | 22:15h | UTC

Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a sixteen-week interval between doses – medRxiv

Commentary: Researchers encourage longer dosing intervals for Pfizer-BioNTech’s COVID-19 vaccine – News Medical

Related:

[Preprint] Covid-19: Longer interval between Covid-19 Pfizer vaccine doses boosts immunity.

[Preprint] Delaying second Pfizer vaccine dose to 12 weeks increases specific antibody response 3.5-fold in people over 80 years of age.

Study Commentary | Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster

3-month interval between first and second dose of Oxford COVID-19 vaccine results in higher vaccine efficacy than 6-week interval

 


CDC Report: Schools without mask requirements were more likely to have Covid-19 outbreaks.

26 Sep, 2021 | 22:10h | UTC

Association Between K–12 School Mask Policies and School-Associated COVID-19 Outbreaks — Maricopa and Pima Counties, Arizona, July–August 2021 – CDC Morbidity and Mortality Weekly Report

Commentary: Schools Without Mask Requirements More Likely to See COVID-19 Outbreaks – U.S. News

 

Commentary on Twitter

 


Opinion | Inappropriate Mixing Clinical and Systemic Thinking: Vaccines in the Young.

26 Sep, 2021 | 22:07h | UTC

Inappropriate Mixing Clinical and Systemic Thinking: Vaccines in the Young – Medium

 


Covid-19 Vaccines – Billions Committed, Millions Delivered.

26 Sep, 2021 | 22:05h | UTC

Billions Committed, Millions Delivered – Think Global Health

 

Commentary on Twitter

 


Just how do deaths due to COVID-19 stack up?

24 Sep, 2021 | 10:07h | UTC

Just How Do Deaths Due to COVID-19 Stack Up? – Think Global Health

 

Commentary on Twitter

 


How patient data underpin COVID-19 research – “Tracking the coronavirus SARS-CoV-2, developing treatments and testing vaccines have relied on access to the health data of millions of people. This massive trove could be used to understand other diseases, but not everyone is convinced”.

24 Sep, 2021 | 10:03h | UTC

How patient data underpin COVID-19 research – Nature

 


No, vaccinated people are not ‘just as likely’ to spread the Coronavirus as unvaccinated people.

24 Sep, 2021 | 10:06h | UTC

No, Vaccinated People Are Not ‘Just as Likely’ to Spread the Coronavirus as Unvaccinated People – The Atlantic

 

Commentary on Twitter

 


COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants.

24 Sep, 2021 | 10:02h | UTC

COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants – Cell

 

Commentary on Twitter

https://twitter.com/Sri_Baqri/status/1438865999281983490

 


Cochrane Special Collection | De-implementation of low-value health care: resource prioritization in the COVID-19 pandemic era.

23 Sep, 2021 | 10:13h | UTC

De-implementation of low-value health care: resource prioritization in the COVID-19 pandemic era – Cochrane Library

Editorial: Making wise choices about low‐value health care in the COVID‐19 pandemic – Cochrane Library

Commentary: Choosing health care wisely when resources are scarce – Evidently Cochrane

 

Commentaries on Twitter

 


Randomized phase 1/2 trial: Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in children and adolescents aged 3–17 years.

23 Sep, 2021 | 10:16h | UTC

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial – The Lancet Infectious Diseases

Related: Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

 


‘Not a zero-sum game’: Sharing vaccines is in countries’ best interests.

23 Sep, 2021 | 10:09h | UTC

‘Not a zero-sum game’: Sharing vaccines is in countries’ best interests – YaleNews

Original article: National interest may require distributing COVID-19 vaccines to other countries – Scientific Reports

 

Commentary on Twitter

 


WHO releases new compendium of innovative health technologies for COVID-19 and other priority diseases.

23 Sep, 2021 | 10:03h | UTC

WHO releases new compendium of innovative health technologies for COVID-19 and other priority diseases – World Health Organization

Compendium: WHO compendium of innovative health technologies for low-resource settings 2021. COVID-19 and other health priorities – World Health Organization

 


New WHO Global Air Quality Guidelines aim to save millions of lives from air pollution.

23 Sep, 2021 | 10:05h | UTC

News release: New WHO Global Air Quality Guidelines aim to save millions of lives from air pollution – World Health Organization

Original Guideline: WHO global air quality guidelines: particulate matter (‎PM2.5 and PM10)‎, ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide

Executive Summary: WHO global air quality guidelines: particulate matter (‎PM2.5 and PM10)‎, ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide

Commentaries:

Millions of deaths could be avoided under new air quality guidelines, WHO says – CNN

Combatting an invisible killer: New WHO air pollution guidelines recommend sharply lower limits – The Conversation

WHO slashes guideline limits on air pollution from fossil fuels – The Guardian

 


Perspective | Sorry, a Coronavirus Infection Might Not Be Enough to Protect You – “Anyone who’d rather have COVID-19 than get vaccinated is taking two gambles: that immunity will stick around, and that symptoms won’t”.

22 Sep, 2021 | 10:23h | UTC

Sorry, a Coronavirus Infection Might Not Be Enough to Protect You – The Atlantic

 


[Press release – not published yet] J&J says booster shot at two months provided 75% protection against moderate to severe COVID-19 globally and 94% of such cases in the U.S.

22 Sep, 2021 | 10:26h | UTC

Press release: Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.

Commentaries:

Johnson & Johnson says additional dose boosts Covid vaccine efficacy – STAT

J&J booster 94% effective against severe COVID, company says – CIDRAP

Two dose version of Johnson & Johnson shot 94% effective against Covid-19, study finds – CNN

 

Commentaries on Twitter

(thread – click for more)

(thread – click for more)

https://twitter.com/hildabast/status/1440363761299124229

 


[Preprint] SARS-like viruses may jump from animals to people hundreds of thousands of times a year.

22 Sep, 2021 | 10:22h | UTC

SARS-like viruses may jump from animals to people hundreds of thousands of times a year – Science

Original study: A strategy to assess spillover risk of bat SARS-related coronaviruses in Southeast Asia – medRxiv

Related:

Did the coronavirus jump from animals to people twice? – Nature

The Origins of SARS-CoV-2: A Critical Review.

The animal origin of SARS-CoV-2 – “Trading of animals susceptible to bat coronaviruses is the likely cause of the COVID-19 pandemic”.

Fauci says natural origins theory of coronavirus is still the most likely.

 


The fight to manufacture COVID vaccines in lower-income countries.

22 Sep, 2021 | 10:21h | UTC

The fight to manufacture COVID vaccines in lower-income countries – Nature

 


Essential Emergency and Critical Care: A consensus among global clinical experts.

22 Sep, 2021 | 10:07h | UTC

Essential Emergency and Critical Care: a consensus among global clinical experts – BMJ Global Health

News releases:

40 steps to reduce deaths from critical illness – London School of Hygiene & Tropical Medicine

40 simple steps to reduce deaths from critical illness – Karolisnka Institutet

 

Commentary on Twitter

 


[Press release – not published yet] Pfizer announces COVID-19 vaccine in children 5 to 11 years produced strong neutralizing antibody responses.

21 Sep, 2021 | 09:57h | UTC

Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years – Pfizer and BioNTech

Commentaries:

Covid-19 vaccine for 5- to 11-year-olds is safe and shows ‘robust’ antibody response, Pfizer says – CNN

Pfizer says COVID-19 vaccine safe, effective in younger children – CIDRAP

Pfizer Covid-19 vaccine generates robust antibody response in children, without serious safety issues, company says – STAT

Expert reaction to press release giving topline results from Pfizer and BioNTech from their phase 2/3 trial looking at safety and antibody responses from their COVID-19 vaccine in children aged 5 to 11 – Science Media Centre

 

Commentaries on Twitter

(thread – click for more)

(thread – click for more)

https://twitter.com/hildabast/status/1439976038964940803

 


Uncoupling vaccination from politics: a call to action.

21 Sep, 2021 | 09:56h | UTC

Uncoupling vaccination from politics: a call to action – The Lancet

 


Six rules that will define our second pandemic winter

21 Sep, 2021 | 09:47h | UTC

Six Rules That Will Define Our Second Pandemic Winter – The Atlantic

 


Podcast: Advance Your Care Planning.

21 Sep, 2021 | 08:51h | UTC

#295 Advance Your Care Planning with Dr. Rebecca Sudore – The Curbsiders

 


5000 alcohol-related cancer deaths could be prevented every year by doubling alcohol taxes in the European Region, says WHO/Europe.

21 Sep, 2021 | 08:52h | UTC

5000 alcohol-related cancer deaths could be prevented every year by doubling alcohol taxes in the European Region, says WHO/Europe – World Health Organization

Original study: Modelling the impact of increased alcohol taxation on alcohol-attributable cancers in the WHO European Region – The Lancet Regional Health – Europe

Related:

Fiscal policies for diet and the prevention of noncommunicable diseases – World Health Organization

The Lancet taskforce on NCDs and economics

To improve global health, tax the things that are killing us – Financial Times

Reducing cardiovascular disease burden through targeted dietary policies

Fiscal policies for the prevention of diseases

 


CDC Report: Moderna’s vaccine associated with greater effectiveness (93%) against Covid-19 hospitalization compared to Pfizer (88%) and J&J (71%) vaccines.

19 Sep, 2021 | 23:48h | UTC

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021 – CDC Morbidity and Mortality Weekly Report

Commentaries:

Moderna’s vaccine is the most effective, but Pfizer and J&J also protect well, CDC-led study says – CNN

CDC: Moderna COVID vaccine most protective against hospital cases – CIDRAP

CDC data: Moderna vaccine has edge in preventing COVID-19 hospitalizations – UPI

 

Commentary on Twitter

 


Does everybody need a booster shot? – “Why some people might need Covid-19 booster shots — and some might not”.

19 Sep, 2021 | 23:43h | UTC

Does everybody need a booster shot? – Vox

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.